Endonovo Therapeutics (ENDV) Revenue (2018 - 2023)
Endonovo Therapeutics has reported Revenue over the past 9 years, most recently at $1520.0 for Q3 2023.
- Quarterly results put Revenue at $1520.0 for Q3 2023, down 86.13% from a year ago — trailing twelve months through Sep 2023 was $255723.0 (up 1699.85% YoY), and the annual figure for FY2022 was $135355.0, up 85.15%.
- Revenue for Q3 2023 was $1520.0 at Endonovo Therapeutics, down from $45200.0 in the prior quarter.
- Over the last five years, Revenue for ENDV hit a ceiling of $148444.0 in Q4 2019 and a floor of $316.0 in Q4 2021.
- Median Revenue over the past 5 years was $39980.0 (2020), compared with a mean of $43088.4.
- Peak annual rise in Revenue hit 38337.66% in 2022, while the deepest fall reached 97.85% in 2022.
- Endonovo Therapeutics' Revenue stood at $148444.0 in 2019, then plummeted by 92.25% to $11500.0 in 2020, then crashed by 97.25% to $316.0 in 2021, then skyrocketed by 38337.66% to $121463.0 in 2022, then crashed by 98.75% to $1520.0 in 2023.
- The last three reported values for Revenue were $1520.0 (Q3 2023), $45200.0 (Q2 2023), and $87540.0 (Q1 2023) per Business Quant data.